Dx dialogues: post anti-CD38 therapy
Dx dialogues: post anti-CD38 therapy
Douglas W. Sborov, MD explains what post anti-CD38 therapy is about.
Up next

Dx dialogues: post anti-CD38 therapy
Jan 14, 2026

Dx dialogues: versatile treatment options across the multiple myeloma landscape
Jan 14, 2026

Dx dialogues: helping physicians identify patients for combination therapies with CAR-T
Jan 14, 2026

Dx dialogues: advancements in treating indolent systemic mastocytosis
Jan 14, 2026

Dx dialogues: other potential treatments for indolent systemic mastocytosis
Jan 14, 2026

Dx dialogues: common and emerging treatments for CRSwNP
Jan 14, 2026

Dx dialogues: new treatment advances & future treatments for COPD
Jan 14, 2026

Dx dialogues: diagnosing indolent systemic mastocytosis
Jan 14, 2026

What you need to know about multiple myeloma
Jul 25, 2017

Dx dialogues: approaches to treating HIV, and how patient behavior influences adherence
Jan 14, 2026

My experience being diagnosed with multiple myeloma
Jan 12, 2023